Last reviewed · How we verify

NCT05738655

Effectiveness of Pumpkin Seed Extract on Improving Blood Sugar Level in Subhealth Subjects

Status unknown NA Last updated 23 February 2024
What this trial tests

NA trial testing Pumpkin seed extract (Low dose) in Diabetes in 60 participants. Status unknown.

Timeline
1 March 2023
Primary endpoint
30 September 2024
31 October 2024

Quick facts

Lead sponsorGreenyn Biotechnology Co., Ltd.
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposeprevention
Enrollment60
Start date1 March 2023
Primary completion30 September 2024
Estimated completion31 October 2024
Sites1 location across Taiwan

Drugs / interventions tested

Conditions studied

Sponsor

Greenyn Biotechnology Co., Ltd.

Who can join

Adults 20 to 75, any sex, with Diabetes or Metabolic Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This randomized, double-blind, placebo-controlled, and parallel clinical study aims to investigate the effectivness of a pumpkin seed extract on blood sugar management in subhealth people.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Diabetes

Currently open trials in the same condition.

Other Greenyn Biotechnology Co., Ltd. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05738655.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing